Item 1(a). | Name of Issuer: |
CARGO Therapeutics, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
1900 Alameda De Las Pulgas, Suite 350
San Mateo, California 94403
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Perceptive Xontogeny Venture Fund II, L.P. (“PXV II”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
PVX II is a Delaware limited partnership
Item 2(d). | Title of Class of Securities: |
Common Stock, $0.001 par value per share (“Common Stock”)
14179K 10 1
Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 38,672,544 shares of Common Stock outstanding following the Issuer’s initial public offering, as reported by the Issuer in its prospectus filed with the Securities and Exchange Commission on November 13, 2023.